2. Search Result
Search Result
Results for "

Cytokine release syndrome

" in MedChemExpress (MCE) Product Catalog:

7

Inhibitors & Agonists

4

Inhibitory Antibodies

1

Natural
Products

Targets Recommended:
Cat. No. Nom du produit Target Áreas de investigación Chemical Structure
  • HY-P9975
    Theralizumab

    TGN1412; TAB08

    		 CD28 Inflammation/Immunology
    Theralizumab (TGN1412) is a humanized lgG4 superagonistic anti-CD28 monoclonal antibody that directly stimulates T cells. Theralizumab can cause cytokine release syndrome (CRS). Theralizumab can be used for the research of rheumatoid arthritis .
    Theralizumab
  • HY-P991015
    Pasritamig

    JNJ-78278343; KLCB-245

    		 CD3 Cancer
    Pasritamig (JNJ-78278343; KLCB-245) is a bispecific T-cell engager (BiTE) that targets the complex of human kallikrein KLK2 and CD3 receptor. Pasritamig redirects the cytotoxicity of T cells to KLK2-expressing tumor cells and induces T cell-mediated lysis of KLK2-expressing prostate cancer cells. Administered via subcutaneous injection, subcutaneous infusion or intravenous infusion, Pasritamig exhibits antitumor activity against metastatic castration-resistant prostate cancer. Pasritamig has a safety profile with an extremely low incidence of cytokine release syndrome and can be safely administered in an outpatient setting. Pasritamig is applicable to the research of metastatic castration-resistant prostate cancer .
    Pasritamig
  • HY-159520
    Ofirnoflastum

    Ofirnoflast; HT-6184

    		 NEKs NOD-like Receptor (NLR) Caspase Apoptosis Pyroptosis NF-κB Cardiovascular Disease Inflammation/Immunology Cancer
    Ofirnoflastum (Ofirnoflast) is an orally active first-in-class allosteric NEK7 inhibitor with an IC50 of 46 nM. Ofirnoflastum binds an allosteric site adjacent to NEK7’s ATP-binding pocket, induces conformational shifts, disrupts NEK7-NLRP3 binding, blocks NLRP3 inflammasome assembly, spares NEK7’s physiological functions, and suppresses caspase-1, caspase-8, NF-κB, and TNF activity. Ofirnoflastum reduces pro-inflammatory cytokine production, suppresses ASC specks, IL-1β release, pyroptotic cell death, and leukemic burden, induces apoptosis and erythroid differentiation, restores hematopoiesis, and improves outcomes in colitis models. Ofirnoflastum can be used for the research of myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia .
    Ofirnoflastum
  • HY-P99754
    Netakimab

    BCD-085

    		 Interleukin Related Infection Inflammation/Immunology
    Netakimab (BCD-085) is a humanized IgG1κ monoclonal anti-IL-17 antibody that binds to and blocks IL-17 and IL-17A activity, including reduction of downstream IL-6 production. Netakimab can be used for the research of moderate-to-severe plaque psoriasis, ankylosing spondylitis, and COVID-19 with cytokine release syndrome . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
    Netakimab
  • HY-177063
    IL-6-IN-2

    		Interleukin Related Infection Inflammation/Immunology
    IL-6-IN-2 is an interleukin-6 (IL-6) inhibitor. IL-6-IN-2 binds to IL-6 at Lys66, Phe74, Gln175, Ser176, and Arg179 via π-π, π-alkyl, hydrogen bond, and hydrophobic interactions to block IL-6/IL-6R heterocomplex formation. IL-6-IN-2 exhibits low gastrointestinal absorption rate. IL-6-IN-2 can be used for the research of cytokine release syndrome, covid-19 .
    IL-6-IN-2
  • HY-P991208
    Flt-3L-Ig (hum/hum)

    human Flt3L; hFlt3L

    		 FLT3 Interleukin Related CCR Inflammation/Immunology
    Flt-3L-Ig (hum/hum) (hFlt3L) is a Flt3 ligand. Flt-3L-Ig (hum/hum) enhances the release of inflammatory cytokines from myeloid cells and dendritic cells in BRGSF-CBC mice induced by OKT3. Flt-3L-Ig (hum/hum) increases the release of IL-2, CCL2 and CXCL10 in an OKT3-dependent manner. Flt-3L-Ig (hum/hum) can be used in studies related to cytokine release syndrome. Flt-3L-Ig (hum/hum) can be used in studies related to psoriasis-like skin inflammation .
    Flt-3L-Ig (hum/hum)
  • HY-N17727
    Divaricatol

    		Interleukin Related TNF Receptor Neurological Disease Inflammation/Immunology
    Divaricatol is an orally ative chromone natural product and an active component in Saposhnikovia divaricata. Divaricatol reduces the release of pro-inflammatory cytokines and restores immune homeostasis by stably binding to 5KIR (a target of the TNF/IL-17 pathway). Divaricatol exerts analgesic effects in mouse models. Divaricatol can be used in the research of pain, diarrhea-predominant irritable bowel syndrome (IBS-D) and qi deficiency syndrome .
    Divaricatol

Demande en ligne

Your information is safe with us. * Required Fields.

Civilité

  

Country or Region *

Nom du demandeur *

 

Nom de l'organisation *

Department *

     

Adresse e-mail *

 

Nom du produit *

Cat. No.

  

Requested quantity *

Numéro de téléphone *

     

Remarques

Demande en ligne

Inquiry Information

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent: